Emphasizing the Pharmacological Potentials of the Methanolic Extract of <i>Wedelia montana</i>: A Prominent Source of Veterinary Medicine.

Abstract

The research focused on <i>Wedelia montana</i> (Blume) Boerl because of its numerous medicinal applications. <i>W. montana</i> belongs to the Asteraceae family. This investigation is intended to analyze the phytochemical content of the methanol extract of <i>W. montana</i> (MEWM) and evaluate its biological features by utilizing in vitro and in vivo models. In vitro examinations determined antioxidant capability, cytotoxic, anthelmintic, and thrombolytic activity of the MEWM. Furthermore, in vivo research included testing for the effects of antidepressants (TST and FST), effects on anxiety (LDT, HBT, and EPM), activities of sedatives (HCT and OFT), and analgesic activities (formalin-induced licking test and tail immersion test). Treatment with MEWM exhibited potent antioxidant properties, with a cytotoxicity test revealing an LC₅₀ value of 256.2 μg/mL, in contrast to 142.28 μg/mL for the positive control. It also resulted in the shortest times for paralysis and mortality at the highest dosage in the anthelmintic assay and notable thrombolytic activity (<i>p</i> < 0.0001). Moreover, MEWM has shown considerable efficacy contingent upon the FST, TST, EPM, HBT, and LDT dose and sedative effects in the OFT and HCT. A 200 mg/mL dosage in the analgesic assessment had no significant impact on the tail immersion test. However, MEWM demonstrated substantial analgesic action in the formalin-induced paw-licking experiment (<i>p</i> < 0.0001). The data indicate that MEWM is a potential source of antioxidant, cytotoxic, anthelmintic, thrombolytic, antidepressant, anxiolytic, sedative, and antinociceptive compounds. Further research is necessary to comprehend its therapeutic benefits completely.